Decision addresses issue of plausibility in invalidation verdict | Case marks first time that Court of Appeal judges held a patent with a single claim to a pharma compound invalid.
The new CEO is currently Denmark CEO and group VP for the firm, who has ‘spearheaded international growth efforts’.
Lawsuit concerns multibillion-dollar bone-strengthening drugs | Alleged dearth of information provided to patent owner before biologics licence application was approved.
Firm says patents-in-suit were developed using $19 million of public money | Biotech also cites “new evidence” in suit with Harvard and 10x.
Latest instalment in dispute over Apple Watch health functionality ends in mistrial | Verdict inconclusive as one out of seven jurors disagrees | Masimo had asked for more than $1.8 billion in damages.
Judge enters default judgment as New Jersey-based firm failed to respond to suit | Defendant allegedly sought to sell 3M-branded masks at inflated prices during the pandemic.
New partner joins from Akin Gump Strauss Hauer & Feld
Proposals include new regulatory protection periods for innovative drugs | Changes are aimed at improving patient access to therapeutics and boosting the EU pharma industry.
First chair litigator served six years at the US Patent and Trademark Office.
Judge rejects notion that tribunal acted unfairly in royalties dispute with Salix | Indian firm wanted payments on sales of antibiotic | Appeal brought under act with ‘high hurdle to surmount’.